Journals / Maltepe Tıp Dergisi / 2010 / Cilt: 2 - Sayı: 1

Current Antipsychotic Use In Pervasive Developmental Disorders

Yaygın Gelişimsel Bozukluklarda Güncel Antipsikotik Kullanımı

Pages
42–49
Publication Date
2010-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, studies of children with PDD who received antipsychotic treatment are reviewed and it is aimed to discuss tolerability end effi cacy of the agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pervasive Developmental Disorders PDD are chronic and neurobiological-basis disorders that are childhood-onset.
📊
Key Findings & Data:Pharmacological interventions are used to eliminate diffi culties which are associated with the disorder, and thus to increase functionality as well as to facilitate the administration of other interventions more effectively.
💡
Conclusion & Impact:In this article, studies of children with PDD who received antipsychotic treatment are reviewed and it is aimed to discuss tolerability end effi cacy of the agents.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:yaygın gelişimsel bozukluk · otizm · antipsikotikler

Abstract

Objective: Pervasive Developmental Disorders PDD are chronic and neurobiological-basis disorders that are childhood-onset. Generally, behavioural and educational interventions are starting points of the treatment. Pharmacological interventions are used to eliminate diffi culties which are associated with the disorder, and thus to increase functionality as well as to facilitate the administration of other interventions more effectively. Antipsychotic medications are frequently used in the treatment of PDD symptoms like aggressive behaviours, tantrums, irritability, self-injury, impulsivity, speech-delay, social withdrawal and mood changes. In this article, studies of children with PDD who received antipsychotic treatment are reviewed and it is aimed to discuss tolerability end effi cacy of the agents.

Özet

Amaç: Yaygın Gelişimsel Bozukluklar YGB , çocukluk çağı başlangıçlı, kronik ve nörobiyolojik temelli bozukluklardır. Genellikle tedaviye başlangıç noktası, davranışçı ve eşitsel müdahalelerdir. Farmakolojik müdahaleler, bozukluğa eşlik eden güçlüklerin ortadan kaldırılarak gerek işlevselliğin arttırılmasında gerekse bu sayede diğer müdahalelerin daha etkin bir şekilde uygulanmasında kullanılmaktadırlar. Antipsikotik ilaçlar, YGB'de görülen saldırganlık, kendine zarar verici davranışlar, öfke nöbetleri, iritabilite, dürtüsellik, konuşma gecikmesi, sosyal çekilme ve duygu durum değişiklikleri semptomlarının tedavisinde sıklıkla kullanılmaktadırlar. Bu yazıda YGB'li çocuklarla antipsikotik kullanılarak yapılmış araştırılmalar gözden geçirilerek, kullanılan ajanların tolere edilebilirlik ve etkinliklerinin tartışılması amaçlanmıştır.

🔖

Cite This Article

KARAMAN, M. G. (2010). Current Antipsychotic Use In Pervasive Developmental Disorders. Maltepe Tıp Dergisi, Cilt: 2 - Sayı: 1, 42–49. https://ajindex.com/articles/231110

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev.Washington, DC:APA, 2000:66-78.
  2. Klin A, Volkmar FR. Asperger syndrome: diagnosis and external validity. Child Adolesc Psychiatr Clin N Am. 2003;12:1-13.
  3. Volkmar F, Cook EH Jr, Pomeroy J, et al. Practi- ce parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999;38 suppl 12:32–54.
  4. Scahill L, Koenig K, Carroll DH, et al. Risperidone approved for the treatment of serious behavioral prob- lems in children with autism. J Child Adolesc Psychiatr Nurs. 2007;20:188-190.
  5. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. Soorya L, Kiarashi J, Hollander E. Psychopharma- cologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:753-771.
  6. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am. 2008;17:787- 801 Nickels K, Katusic SK, Colligan RC, et al. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Dev Behav Pediatr. 2008;29:75-81.
  7. Mandell DS, Morales KH, Marcus SC, et al. Psy- chotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121:441-448.
  8. Leskovec TJ, Rowles BM, Findling RL. Pharmaco- logical treatment options for autism spectrum disor- ders in children and adolescents. Harv Rev Psychiatry. 2008;16:97-112.
  9. Dover CJ, Le Couteur A. How to diagnose autism. Arch Dis Child. 2007;92:540-545.
  10. Chavez B, Chavez-Brown M, Sopko MA Jr, et al. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs. 2007;9:249- 266. Miral S, Gencer O, Inal-Emiroglu FN, et al. Rispe- ridone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17:1-8.
  11. Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008;17:713-738.
  12. McCracken JT, McGough J, Shah B, et al; Rese- arch Units on Pediatric Psy